Compare RYAM & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RYAM | REPL |
|---|---|---|
| Founded | 1926 | 2015 |
| Country | United States | United States |
| Employees | 2325 | N/A |
| Industry | Paper | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 751.8M | 692.8M |
| IPO Year | 2014 | 2018 |
| Metric | RYAM | REPL |
|---|---|---|
| Price | $10.81 | $7.52 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 9 |
| Target Price | ★ $14.00 | $11.13 |
| AVG Volume (30 Days) | ★ 1.4M | 1.3M |
| Earning Date | 03-03-2026 | 02-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 5.25 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,466,397,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.22 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.35 | $2.68 |
| 52 Week High | $11.85 | $13.24 |
| Indicator | RYAM | REPL |
|---|---|---|
| Relative Strength Index (RSI) | 56.85 | 51.39 |
| Support Level | $6.91 | $6.81 |
| Resistance Level | $11.85 | $8.07 |
| Average True Range (ATR) | 0.46 | 0.50 |
| MACD | -0.11 | 0.02 |
| Stochastic Oscillator | 51.72 | 46.12 |
Rayonier Advanced Materials Inc engaged in the production and sale of high-purity cellulose and other cellulose-based materials derived from renewable wood fiber. The company operates through five segments: Cellulose Specialties, which produces highly purified cellulose used in products such as filters, pharmaceuticals, food additives and electronics; Biomaterials, which produces products including biofuels, lignosulfonates and other bio-based chemicals; Cellulose Commodities, which manufactures absorbent and viscose pulp used in textiles and hygiene products; Paperboard, which produces coated paperboard used for packaging and printing applications; and High-Yield Pulp, which produces pulp used in paperboard, packaging and printing paper products.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.